GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Modalis Therapeutics Corp (TSE:4883) » Definitions » Enterprise Value

Modalis Therapeutics (TSE:4883) Enterprise Value : 円1,342.62 Mil (As of Jun. 10, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Modalis Therapeutics Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Modalis Therapeutics's Enterprise Value is 円1,342.62 Mil. Modalis Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was 円-2,311.84 Mil. Therefore, Modalis Therapeutics's EV-to-EBIT ratio for today is -0.58.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Modalis Therapeutics's Enterprise Value is 円1,342.62 Mil. Modalis Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was 円-2,311.84 Mil. Therefore, Modalis Therapeutics's EV-to-EBITDA ratio for today is -0.58.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Modalis Therapeutics's Enterprise Value is 円1,342.62 Mil. Modalis Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was 円0.00 Mil. Therefore, Modalis Therapeutics's EV-to-Revenue ratio for today is .


Modalis Therapeutics Enterprise Value Historical Data

The historical data trend for Modalis Therapeutics's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Modalis Therapeutics Enterprise Value Chart

Modalis Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial - 57,655.03 12,820.82 6,903.24 2,665.11

Modalis Therapeutics Quarterly Data
Dec18 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,970.08 6,187.13 2,839.54 2,665.11 2,129.07

Competitive Comparison of Modalis Therapeutics's Enterprise Value

For the Drug Manufacturers - Specialty & Generic subindustry, Modalis Therapeutics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Modalis Therapeutics's Enterprise Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Modalis Therapeutics's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Modalis Therapeutics's Enterprise Value falls into.



Modalis Therapeutics Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Modalis Therapeutics's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Modalis Therapeutics's Enterprise Value for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Modalis Therapeutics  (TSE:4883) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Modalis Therapeutics's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1342.622/-2311.835
=-0.58

Modalis Therapeutics's current Enterprise Value is 円1,342.62 Mil.
Modalis Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-2,311.84 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Modalis Therapeutics's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=1342.622/-2311.835
=-0.58

Modalis Therapeutics's current Enterprise Value is 円1,342.62 Mil.
Modalis Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-2,311.84 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Modalis Therapeutics's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=1342.622/0
=

Modalis Therapeutics's current Enterprise Value is 円1,342.62 Mil.
Modalis Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Modalis Therapeutics Enterprise Value Related Terms

Thank you for viewing the detailed overview of Modalis Therapeutics's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Modalis Therapeutics (TSE:4883) Business Description

Traded in Other Exchanges
N/A
Address
16-5 Nihombashi-Kabuto-cho, Chuo-ku, Tokyo, JPN, 103-0026
Modalis Therapeutics Corp is a drug development company. It is engaged in research and development of Gene Therapy using core platform technology, non-editing CRISPR technology (CRISPR-GNDM). The company's products in pipeline are MDL-201, MDL-202, MDL-204, MDL-205, MDL-206, MDL-101, and MDL-102.

Modalis Therapeutics (TSE:4883) Headlines

No Headlines